| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10591871 | Bioorganic & Medicinal Chemistry Letters | 2014 | 5 Pages |
Abstract
The G protein-coupled receptor 40 (GPR40) mediates enhancement of glucose-stimulated insulin secretion in pancreatic β cells. The GPR40 agonist has been attracting attention as a novel insulin secretagogue with glucose dependency for the treatment of type 2 diabetes. The optimization study of compound 1 led to a potent and bioavailable GPR40 agonist 24, which showed insulin secretion and glucose lowering effects in rat OGTT. Compound 24 is a potential lead compound for a novel insulin secretagogue with a low risk of hypoglycemia.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Rieko Takano, Masao Yoshida, Masahiro Inoue, Takeshi Honda, Ryutaro Nakashima, Koji Matsumoto, Tatsuya Yano, Tsuneaki Ogata, Nobuaki Watanabe, Narihiro Toda,